Exelixis Clinical Trials
Ongoing Exelixis-sponsored global, randomized phase 3 pivotal trials of cabozantinib include the METEOR study in metastatic renal cell cancer and the CELESTIAL study in advanced hepatocellular cancer.
We are also continuing to follow patients enrolled in COMET-2, our phase 3 trial of cabozantinib in metastatic castration-resistant prostate cancer (CRPC), and we anticipate data from that study before the end of 2014. We also anticipate results from the overall survival analysis of EXAM, our phase 3 trial in metastatic medullary thyroid carcinoma, by year-end.
You can access a detailed list of cabozantinib clinical studies posted on ClinicalTrials.gov. For further information regarding all clinical trials, please contact Exelixis Medical Information at 1-888-EXELIXIS (1-888-393-5494) or at firstname.lastname@example.org.